Oral Hepatitis C antivirals have increased cure rates close to 100%!


The development of oral direct acting antivirals has pushed cure rates close to 100%. Harvoni is used for genotype 1 patients and many only require 8 weeks of therapy. Epclusa is effective for all genotypes and was released in June 2016. Mavyret is effective for all genotypes and can be taken by patients with renal failure. Vosevi contains three ingredients and is used for the few patients who fail their initial treatment. Zepatier is a complicated drug that will be pushed out of the market by Epclusa and Mavyret. These are very happy times for patients with hepatitis C.

The
CDC recommends that all Americans born between 1945 and 1965 be tested one time for HCV. One-third of persons with HCV die from complications of cirrhosis. We can avoid premature death from HCV if we are aggressive in identifying infected patients. Five million Americans are infected and more than one million will die from delayed diagnosis. The CDC has pointed out the HCV is the number one fatal infection in the USA and kills about 20,000 persons each year. I am an advocate for patients infected with HCV.

I am a board certified in internal medicine and gastroenterology. In addition, I completed 2 years of
residency in pathology at Duke University Medical Center from 1977 to 1979. I have been a physician for 40 years. I spend about 98% of my time treating patients with chronic viral hepatitis C. We have more than 2,000 cured patients.

I enjoy helping as many patients as possible cure this infection. Therapy is now less expensive, and, except for patients with some Medicaid insurance policies, treatment is available.

My office: 1009A Dupont Square North, Louisville KY 40207  phone: 502-894-9950

I can give information, but cannot practice medicine over the internet.  Patients should consult a medical provider who treats large numbers of HCV infected patients. Bennet Cecil, MD